Lv21
168 积分 2024-07-23 加入
Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma
41分钟前
已完结
Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group
44分钟前
已关闭
PI3K/Akt and HIF‑1 signaling pathway in hypoxia‑ischemia (Review)
5天前
已完结
A Phase II Evaluation of Cediranib in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
13天前
已完结
Guequén A, Carrasco R, Zamorano P, Rebolledo L, Burboa P, Sarmiento J, Boric MP, Korayem A, Durán WN, Sánchez FA
25天前
已完结
Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta
25天前
已完结
Overexpression of estrogen receptor-alpha in the endometrial carcinoma cell line Ishikawa: inhibition of growth and angiogenic factors
30天前
已完结
Expression of vascular endothelial growth factor (VEGF) and assessment of microvascular density with CD34 as prognostic markers for endometrial carcinoma
30天前
已关闭
EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF
30天前
已完结
皖公网安备34019202002308
